The 5th meeting of the International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) was held in Berlin, Germany and brought to light a huge array of exciting updates within the transplant field, across numerous disease areas.

Explore the expansive and unique information on controversies important to stem cell transplantation and cellular therapies heard at this meeting.

View all videos

COSTEM 2019

The 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies
Berlin, 24-27 October

COSTEM 2019

The 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies
Berlin, 24-27 October

The 5th meeting of the International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) was held in Berlin, Germany and brought to light a huge array of exciting updates within the transplant field, across numerous disease areas.

Explore the expansive and unique information on controversies important to stem cell transplantation and cellular therapies heard at this meeting.

View all videos

Transplantation

View all
1:35
Optimal GVHD prophylaxis in T-cell repleted haploidentical transplantation
Christopher Kanakry • 25 Oct 2019
4:25
Post-transplant cyclophosphamide mechanisms
Christopher Kanakry • 26 Oct 2019
1:45
getITD for FLT3-ITD-based MRD monitoring in AML
Lars Bullinger • 26 Oct 2019
3:15
Is haploidentical the best curative option for sickle cell disease?
Miguel Abboud • 26 Oct 2019

GvHD

View all
3:36
Is endothelial protection effective for GVHD, VOD and TMA?
Mohamad Mohty • 26 Oct 2019
1:58
ASCT in the outpatient setting
Rainer Storb

MRD

View all
3:03
Improving AML outcomes
Charles Craddock
3:13
Is MRD monitoring prior to allograft standard in AML?
Michael Heuser • 25 Oct 2019

Multiple Myeloma

View all
2:01
The Chinese CAR-T experience
Peihua Lu • 25 Oct 2019
1:22
MM: stem cell mobilization regimens with and without plerixafor
Nicolaus Kröger • 25 Oct 2019

Lymphoma

View all
2:19
CARs: driving the field forward
Michael Bishop • 26 Oct 2019
3:47
Can CAR-T cells replace ASCT in DLBCL?
Arnon Nagler • 26 Oct 2019

Leukemia

View all
2:45
Optimal preparative regimen for AML
Charles Craddock • 25 Oct 2019
3:07
How will CAR-T cells help us cure Ph+ ALL?
Peter Bader • 25 Oct 2019

Anemia

View all
1:38
Cord vs. haplo in SAA
Rainer Storb • 26 Oct 2019
3:42
Aplastic anemia: treatment options in 2019
Antonio Risitano • 26 Oct 2019
Optimal GVHD prophylaxis in T-cell repleted haploidentical transplantation 1:35
Optimal GVHD prophylaxis in T-cell repleted haploidentical transplantation
Christopher Kanakry • 25 Oct 2019
Gilteritinib for FLT+ R/R AML 1:20
Gilteritinib for FLT+ R/R AML
Giovanni Martinelli • 26 Oct 2019
Post-transplant cyclophosphamide mechanisms 4:25
Post-transplant cyclophosphamide mechanisms
Christopher Kanakry • 26 Oct 2019
getITD for FLT3-ITD-based MRD monitoring in AML 1:45
getITD for FLT3-ITD-based MRD monitoring in AML
Lars Bullinger • 26 Oct 2019
Transplant-associated thrombotic microangiopathy (TA-TMA) 2:20
Transplant-associated thrombotic microangiopathy (TA-TMA)
Sergio Giralt • 25 Oct 2019
Is haploidentical the best curative option for sickle cell disease? 3:15
Is haploidentical the best curative option for sickle cell disease?
Miguel Abboud • 26 Oct 2019
Cord vs. haplo in SAA 1:38
Cord vs. haplo in SAA
Rainer Storb • 26 Oct 2019
Donor type and source of choice 1:55
Donor type and source of choice
Leo Luznik • 26 Oct 2019
The “controversial situations” seen in FLT3-mutated AML patients 0:56
The “controversial situations” seen in FLT3-mutated AML patients
Lars Bullinger • 25 Oct 2019
The evolving role of maintenance therapy post-ASCT in MM 2:52
The evolving role of maintenance therapy post-ASCT in MM
Philip McCarthy • 26 Oct 2019
Aplastic anemia: treatment options in 2019 3:42
Aplastic anemia: treatment options in 2019
Antonio Risitano • 26 Oct 2019
Immune reconstitution after HLA-HSCT 0:55
Immune reconstitution after HLA-HSCT
Leo Luznik • 26 Oct 2019
Transplantation in an evolving therapy landscape 1:13
Transplantation in an evolving therapy landscape
Peter Bader • 26 Oct 2019
Should upfront CAR-T be part of the early MM treatment? 3:07
Should upfront CAR-T be part of the early MM treatment?
Philip McCarthy • 26 Oct 2019
CARs: driving the field forward 2:19
CARs: driving the field forward
Michael Bishop • 26 Oct 2019
No role for tandem ASCT in MM? 1:10
No role for tandem ASCT in MM?
Sergio Giralt • 26 Oct 2019
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals